Clinical value of TNF, IL-6, and IL-10 gene polymorphic markers in chronic glomerulonephritis


Cite item

Full Text

Abstract

Aim. To study the association of the polymorphic markers (PMs) G(-238)A of the TNF gene, G(–174)C of the IL-6 gene, and G(–1082)A of the IL-10 gene with the clinical characteristics of chronic glomerulonephritis (CGN) and a response to immunosuppressive therapy (IST). Subjects and methods. Clinical syndromes at the time of diagnosis, the morphological types of nephritis, and a response to IST were analyzed in relation to the carriage of the examined PMs of the TNF, IL-6, and IL-10 genes in 102 patients with CGN. Results. No association was found between the PM G(-238)A of the TNF gene and the clinical features of CGN. The carriers of the C allele of the PM G(-174) C of the IL-6 gene versus the homozygous individuals were observed to have more frequently kidney dysfunction at the time of diagnosis (р=0.014). Hypertension was more common in the carriers of the AA genotype of the PM G(-1082)A of the IL-10 gene (p=0.023); moreover, they tended to have a more frequent concurrence of nephrotic syndrome and hypertension (p=0.082). Analysis of the distribution of the morphological types of CGN disclosed that the proliferative variants were more common in the patients with the GG genotype (the TNF gene) as compared to the A allele carriers (p=0.067); and the nonproliferative forms were in the individuals homozygous for GG (the IL-6 gene) as compared to the C allele carriers (p=0.067). Examination of an IST response showed that a complete response at 12 months of treatment occurred more frequently in the carriers of the C allele of the IL-6 gene (p=0.045) and in those of the GG genotypes of the IL-10 gene (p=0.030). Conclusion. There was an association of the PMs G(–174)C of the IL-6 gene and G(–1082)A of the IL-10 gene with the clinical features of CGN and a response to IST.

References

  1. Вашурина Т.В., Сергеева Т.В. Цитокины и адгезивные молекулы в патогенезе хронического гломерулонефрита. Нефрология и диализ. 2002;3:171-181.
  2. Богомазов С.Ю., Гладских О.П., Иванов А.А. и др. Цитокины и внеклеточный матрикс при экспериментальных гломерулопатиях. Архив патологии. 1997;59(6):45-50.
  3. Chen A, Chen W, Sheu L, Lin C. Pathogenesis of IgA nephropathy: In vitro activation of human mesangial cells by IgA immune complex leads to cytokine secretion. J Pathol. 1994;173(2):119-126. doi: 10.1002/path.1711730208.
  4. Liang Y, Zhang J, Zhou Y, Xing G, Zhao G, Liu Z. Proliferation and Cytokine Production of Human Mesangial Cells Stimulated by Secretory IgA Isolated from Patients with IgA Nephropathy. Cel Physiol Biochem. 2015;36(5):1793-1808. doi: 10.1159/000430151.
  5. Couser W. Pathogenesis of glomerular damage in glomerulonephritis. Nephrol Dial Transplant. 1998;13(90001):10-15. doi: 10.1093/ndt/13.suppl_1.10.
  6. Waldherr R, Noronha I, Niemir Z, KrпїЅger C, Stein H, Stumm G. Expression of cytokines and growth factors in human glomerulonephritides. Pediatr Nephrol. 1993;7(4):471-478. doi: 10.1007/bf00857578.
  7. Ifuku M, Miyake K, Watanebe M et al. Various Roles of Th Cytokine mRNA Expression in Different Forms of Glomerulonephritis. Am J Nephrol. 2013;38(2):115-123. doi: 10.1159/000353102.
  8. Чеботарева Н.В., Бобкова И.Н., Непринцева Н.В. и др. Мочевые маркеры повреждения подоцитов: значение для оценки течения и прогноза хронического гломерулонефрита. Терапевтический архив. 2015;6:34-39.
  9. Чурносов М.И., Калмыкова Е.В., Некипелова Е.В., Рудых Н.А., Аристова И.К., Должников А.А. Аллельные варианты генов интерлейкинов при хроническом гломерулонефрите. Цитокины и воспаление. 2010;9(2):37-41.
  10. Петросян Э.К., Цыгин А.Н., Шестаков А.Е., Носиков В.В. Роль генетического полиморфизма интерлейкинов 4 и 13 в развитии нефротического синдрома с минимальными изменениями у детей и подростков. Педиатрия. Журнал им. Г.Н. Сперанского. 2006; 5: 7-10.
  11. Agrawal S, Tripathi G, Jafar T et al. Does cytokine gene polymorphism affect steroid responses in idiopathic nephrotic syndrome? Indian J Med Scie. 2008;62(10):383. doi: 10.4103/0019-5359.44017.
  12. Калмыкова Е.В., Полякова И.С., Прощаев К.И. и др. Изучение взаимосвязей молекулярно-генетических маркеров интерлейкинов с клиническим течением хронического гломерулонефрита. Вестник Российского университета дружбы народов. Серия: Медицина. 2009;4:619-620.
  13. Parry R, Gillespie K, Parnham A, Clark A, Mathieson P. Interleukin-4 and interleukin-4 receptor polymorphisms in minimal change nephropathy. Clin Sci. 1999;96(6):665-668. doi: 10.1042/cs0960665.
  14. Vázquez-Huerta DI, Alvarez-Rodríguez BA, Topete-Reyes JF et al. Tumor necrosis factor alpha -238 G/A and -308 G/A polymorphisms and soluble TNF-α levels in chronic kidney disease: correlation with clinical variables. Int J Clin Exp Med. 2014;7(8):2111-2119.
  15. Amoli MM, Martin J, Miranda-Filloy JA et al. Lack of association between interleukin-6 promoter polymorphism at position -174 and Henoch-Schönlein purpura. Clin Exp Rheumatol. 2007;25(1 Suppl 44):S6-9.
  16. Buraczynska M, Mierzicki P, Buraczynska K, Dragan M, Ksiazek A. Tumor necrosis factor-alpha gene polymorphism correlates with cardiovascular disease in patients with end-stage renal disease. Mol Diag Ther. 2007;11(4):257-263. doi: 10.1007/bf03256247.
  17. Ranganath P, Tripathi G, Sharma R, Sankhwar S, Agrawal S. Role of non-HLA genetic variants in end-stage renal disease. Tissue Antigens. 2009;74(2):147-155. doi: 10.1111/j.1399-0039.2009.01276.x.
  18. Brull D, Montgomery H, Sanders J et al. Interleukin-6 Gene -174G>C and -572G>C Promoter Polymorphisms Are Strong Predictors of Plasma Interleukin-6 Levels After Coronary Artery Bypass Surgery. Arterioscler, Thrombos, Vasc Biol. 2001;21(9):1458-1463. doi: 10.1161/hq0901.094280.
  19. Семенова Н.А., Рязанцева Н.В., Новицкий В.В. и др. Роль полиморфизма гена IL6 -174C/G в развитии хронической HCV-инфекции. Бюллетень сибирской медицины. 2010;5:93-97.
  20. Muller-Steinhardt M, Hartel C, Muller B, Kirchner H, Fricke L. The interleukin-6 -174 promoter polymorphism is associated with long-term kidney allograft survival. Kidney Int. 2002; 62(5):1824-1827. doi: 10.1046/j.1523-1755.2002.00609.x.
  21. Chiappelli M, Tampieri C, Tumini E et al. Interleukin-6 gene polymorphism is an age-dependent risk factor for myocardial infarction in men. Int J Immunogenet. 2005;32(6):349-353. doi: 10.1111/j.1744-313x.2005.00537.x.
  22. Sie M. Interleukin 6 -174 G/C Promoter Polymorphism and Risk of Coronary Heart Disease: Results from the Rotterdam Study and a Meta-Analysis. Arterioscler, Thrombos, Vasc Biol. 2006;26(1):212-217. doi: 10.1161/01.atv.0000194099.65024.17.
  23. Losito A, Kalidas K, Santoni S, Jeffery S. Association of interleukin-6 -174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int. 2003;64(2):616-622. doi: 10.1046/j.1523-1755.2003.00119.x.
  24. Del Prete G, De Carli M, Almerigogna F et al. Human IL-10 is produced by both Type 1 Helper (Th1) and Type 2 Helper (Th2) T cell clones and inhibits their antigen-specific proliferation and Cytokine Production. J Immunol. 1993;150:353-360.
  25. Fiorentino DF, Zlotnik A, Mosmann TR et al. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991;147:3815-3822.
  26. Moore KW, O’Garra A, de Waal Malefyt R et al. Interleukin-10. Annu Rev Immunol. 1993;1:165-190.
  27. Turner D, Williams D, Sankaran D, Lazarus M, Sinnott P, Hutchinson I. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogen. 1997;24(1):1-8. doi: 10.1111/j.1365-2370.1997.tb00001.x.
  28. Eskdale J, Gallagher G, Verweij C, Keijsers V, Westendorp R, Huizinga T. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Scie. 1998;95(16):9465-9470. doi: 10.1073/pnas.95.16.9465.
  29. Girndt M, Ulrich C, Kaul H, Sester U, Sester M, Kohler H. Uremia-associated immune defect: the IL-10-CRP axis. Kidney Int. 2003;63:S76-S79. doi: 10.1046/j.1523-1755.63.s84.14.x.
  30. Краснова Т.Н., Самоходская Л.М., Иваницкий Л.В., Корогодина А.Д., Борисов Е.Н., Никифорова Н.В., Новиков П.И., Камалов А.А., Мухин Н.А. Влияние полиморфизмов генов интерлейкина-10 и интерлейкина-28 на развитие и течение волчаночного нефрита. Терапевтический архив. 2015;87(6):40-44.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies